Platelet Reactivity Clinical Trial
Official title:
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. Increased evidence showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. Therefore, the investigators performed this study to observe the efficacy of ticagrelor in comparison to clopidogrel in Chinese patients with stable CAD.
Ticagrelor is a novel, direct-acting, reversibly binding P2Y12 receptor antagonist. When related with clopidogrel, ticagrelor exhibits a more potent and more predictable antiplatelet effect with a faster onset and offset of action. Current guidelines give a recommendation on the use of dual antiplatelet therapy support ticagrelor 90 mg twice daily over clopidogrel 75 mg daily in addition to aspirin in CAD patients. However, increasing evidence showed ticagrelor increased the risk of bleeding. Recent studies showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. So the investigators performed this randomized, single-blind, crossover clinical trial to observe the effects of standard-dose ticagrelor and standard-dose clopidogrel on platelet reactivity in Chinese patients with stable CAD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02808039 -
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
|
N/A | |
| Completed |
NCT01961856 -
Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
|
Phase 3 | |
| Recruiting |
NCT03525145 -
Platelet Reactivity And Clinical ThrombotIC Events Study
|
||
| Completed |
NCT01463150 -
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
| Completed |
NCT01463163 -
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
| Recruiting |
NCT03614832 -
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
|
Phase 4 | |
| Completed |
NCT01835353 -
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
| Recruiting |
NCT05773989 -
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
|
Phase 4 | |
| Completed |
NCT01511471 -
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
|
Phase 3 | |
| Completed |
NCT00827346 -
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
|
Phase 2/Phase 3 | |
| Completed |
NCT00976196 -
Platelet Hyperreactivity Project
|
N/A | |
| Recruiting |
NCT05367336 -
Platelet Reactivity With Fentanyl, Morphine, or no Narcotic
|
Early Phase 1 | |
| Completed |
NCT03679091 -
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
|
Phase 4 | |
| Recruiting |
NCT05657041 -
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
|
Phase 2/Phase 3 |